Having spent the past decade building its position in neurology and immunology, Belgian biopharma UCB’s pipeline strategy is now focused on turning these core areas into the next generation of growth. Together, the deals have brought novel approaches spanning regenerative medicine, T-cell engagement, and immune modulation into UCB’s pipeline. In this article, we take a closer look at UCB’s pipeline strategy and the deals helping to shape its future. Neurology: From seizure control to disease-modifying therapiesNeurology is the other major pillar of UCB’s strategy, and here the company has an especially strong foundation to build on. Can UCB’s focused pipeline strategy deliver long-term growth?